BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh

 You are in: Business
Front Page 
UK Politics 
Market Data 
Your Money 
Business Basics 
Talking Point 
In Depth 

Commonwealth Games 2002

BBC Sport

BBC Weather

Tuesday, 11 December, 2001, 23:00 GMT
Merck sees flat earnings
Pills being poured into a container
Merck's profits aren't flowing as freely as it would like
The US pharmaceuticals giant Merck has predicted that its earnings in 2002 will be little changed on those for this year.

The company says it will be hit by the expiration of patents on key drugs, and slower sales growth for its key arthritis drug Vioxx.

The announcement surprised analysts and sent its share price sharply downwards on Wall Street.

"We anticipate earnings per share at the same level as 2001," said the company's chief financial officer Judy Lewent.

"This 2002 guidance is not at the level that we would have liked to deliver."


Merck's share price slumped 9.4% to close at $60.70.

The news also cast a shadow across the rest of the market, reversing earlier gains and pushing the Dow Jones index back below the 10,000 level.

Analysts said they had been expecting some slowdown in growth next year, but said the news from Merck was far worse than they had been expecting.

Merck faces the loss of patents on some of its top medicines next year in the US, including hypertension treatment Prinivil and ulcer medicine Prilosec.

See also:

20 Jul 01 | Business
Merck's profits up, but growth slows
22 Jun 01 | Business
Drug giant warns of lower profits
20 Apr 01 | Business
New drugs boost Merck's profits
07 Mar 01 | Africa
US firm offers cheap Aids drugs
17 Jul 01 | Business
Drugs firms beat the slowdown
Internet links:

The BBC is not responsible for the content of external internet sites

Links to more Business stories are at the foot of the page.

E-mail this story to a friend

Links to more Business stories